X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2085) 2085
Publication (106) 106
Book Review (38) 38
Book Chapter (5) 5
Dissertation (4) 4
Conference Proceeding (3) 3
Web Resource (3) 3
Data Set (2) 2
Magazine Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1372) 1372
esomeprazole (1253) 1253
male (903) 903
index medicus (885) 885
female (860) 860
omeprazole (733) 733
proton pump inhibitors (726) 726
gastroenterology & hepatology (707) 707
middle aged (680) 680
adult (636) 636
pharmacology & pharmacy (552) 552
treatment outcome (502) 502
aged (456) 456
gastroesophageal reflux - drug therapy (413) 413
esomeprazole - therapeutic use (407) 407
proton pump inhibitors - therapeutic use (369) 369
lansoprazole (362) 362
esomeprazole - administration & dosage (351) 351
anti-ulcer agents - therapeutic use (297) 297
gastroesophageal reflux (285) 285
rabeprazole (265) 265
gastroesophageal-reflux disease (259) 259
helicobacter pylori (229) 229
pantoprazole (228) 228
therapy (228) 228
proton pump inhibitor (226) 226
drug therapy, combination (219) 219
proton pump inhibitors - administration & dosage (218) 218
anti-ulcer agents - administration & dosage (214) 214
esomeprazole - adverse effects (204) 204
helicobacter infections - drug therapy (202) 202
management (202) 202
adolescent (195) 195
pharmacokinetics (195) 195
double-blind method (189) 189
prospective studies (187) 187
young adult (182) 182
symptoms (180) 180
proton pump inhibitors - adverse effects (179) 179
efficacy (178) 178
gastroesophageal reflux disease (177) 177
double-blind (175) 175
erosive esophagitis (170) 170
medicine & public health (165) 165
dose-response relationship, drug (161) 161
medicine, general & internal (156) 156
aged, 80 and over (154) 154
drug administration schedule (150) 150
care and treatment (147) 147
hydrogen-ion concentration (146) 146
esophagitis (144) 144
omeprazole - therapeutic use (136) 136
gerd (133) 133
internal medicine (129) 129
risk factors (127) 127
time factors (121) 121
disease (120) 120
drug interactions (118) 118
esomeprazole - pharmacology (118) 118
drug therapy (117) 117
metaanalysis (116) 116
anti-bacterial agents - therapeutic use (115) 115
clinical trials (113) 113
infection (113) 113
heartburn (112) 112
proton pump inhibitors - pharmacology (112) 112
anti-ulcer agents - adverse effects (110) 110
cross-over studies (110) 110
risk (110) 110
gastroesophageal reflux - complications (109) 109
pharmacology/toxicology (109) 109
administration, oral (107) 107
helicobacter pylori - drug effects (104) 104
eradication (103) 103
prevalence (102) 102
quality-of-life (102) 102
dosage and administration (99) 99
abridged index medicus (98) 98
gastroesophageal reflux - diagnosis (98) 98
proton-pump inhibitors (97) 97
2-pyridinylmethylsulfinylbenzimidazoles (96) 96
health aspects (96) 96
amoxicillin (95) 95
severity of illness index (95) 95
clarithromycin (92) 92
diagnosis (92) 92
esomeprazole 40 mg (92) 92
omeprazole - administration & dosage (91) 91
animals (89) 89
aspirin (89) 89
research (89) 89
analysis (88) 88
endoscopy (88) 88
amoxicillin - therapeutic use (86) 86
esophagitis, peptic - drug therapy (86) 86
triple therapy (86) 86
gastroenterology (83) 83
gastroesophageal-reflux (83) 83
anti-ulcer agents - pharmacology (82) 82
intragastric ph (82) 82
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1931) 1931
German (34) 34
French (33) 33
Spanish (20) 20
Chinese (18) 18
Russian (18) 18
Korean (14) 14
Japanese (6) 6
Czech (3) 3
Dutch (3) 3
Italian (3) 3
Swedish (3) 3
Hungarian (2) 2
Polish (2) 2
Portuguese (2) 2
Bulgarian (1) 1
Danish (1) 1
Norwegian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Supercritical Fluids, ISSN 0896-8446, 12/2019, Volume 154, p. 104606
Production of micro- and nano-sized particles through supercritical fluid (SCF) technology needs substantial measurements of solubility data. In this work, for... 
Equation of state (EoS) | Esomeprazole (ESM) | Empirical and thermodynamic modeling | Solubility measurement | Supercritical carbon dioxide (SC−CO2)
Journal Article
Talanta, ISSN 0039-9140, 11/2019, Volume 204, pp. 817 - 825
This paper reports an effective approach for the fabrication of a per-4-chlorophenylcarbamate-β-cyclodextrin (β-CD) bonded chiral stationary phase (CPCDP) in... 
β-Cyclodextrin (β-CD) derivatives | Enantioseparation | Chiral stationary phases | High-performance liquid chromatography | LANSOPRAZOLE | RABEPRAZOLE | ESOMEPRAZOLE | CHEMISTRY, ANALYTICAL | PERFORMANCE | OMEPRAZOLE | BETA-CYCLODEXTRIN DERIVATIVES | PANTOPRAZOLE | LIQUID-CHROMATOGRAPHY | DRUGS | SEPARATION | beta-Cyclodextrin (beta-CD) derivatives
Journal Article
Esophagus, ISSN 1612-9059, 10/2019, Volume 16, Issue 4, pp. 377 - 381
To investigate the efficacy of long-term (52 weeks) maintenance therapy by 10-mg vonoprazan administration for proton pump inhibitor-resistant reflux... 
Vonoprazan | Medicine & Public Health | Maintenance therapy | Gastroenterology | Thoracic Surgery | Surgical Oncology | PPI-resistant reflux esophagitis | RABEPRAZOLE | LANSOPRAZOLE | COMPETITIVE ACID BLOCKER | ESOMEPRAZOLE 20MG | GASTROENTEROLOGY & HEPATOLOGY | Gastroesophageal reflux | Esophagitis | Medical colleges | Endoscopy | Gastrin
Journal Article
European Journal of Drug Metabolism and Pharmacokinetics, ISSN 0378-7966, 10/2019, Volume 44, Issue 5, pp. 713 - 717
A recent report indicated that the pharmacodynamic interaction between clopidogrel and vonoprazan leading to attenuation of the anti-platelet effect of... 
Pharmaceutical Sciences/Technology | Medical Biochemistry | Biomedicine | Human Physiology | Pharmacology/Toxicology | Pharmacy | ESOMEPRAZOLE | CLOPIDOGREL | PHARMACOKINETICS | COMPETITIVE ACID BLOCKER | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS
Journal Article
Helicobacter, ISSN 1083-4389, 10/2019, Volume 24, Issue 5, pp. e12606 - n/a
Background Several studies have shown that Pylera® (three‐in‐one capsules containing 140 mg bismuth potassium subcitrate, 125 metronidazole, and tetracycline... 
first‐line therapy | esomeprazole | Helicobacter pylori infection | Pylera | Ranitidine | Toxicity | Population studies | Infections | Patients | Omeprazole | Urea | Absorption | Motivation | Helicobacter pylori | Bismuth | Metronidazole | Potassium
Journal Article
Polymer-Plastics Technology and Materials, ISSN 2574-0881, 09/2019, Volume 58, Issue 14, pp. 1507 - 1520
The study aimed to develop chemically crosslinked poly(2-methoxyethyl methacrylate-co-acrylic acid) (p(MEMA-co-AA)) microhydrogels as carriers for... 
controlled drug delivery | Acrylic acid | MEMA | pharmacokinetics | crosslinking | copolymeric microhydrogels | HPLC | ESOMEPRAZOLE | POLYMER SCIENCE | ACID | MICROSPHERES | CROSS-LINKED HYDROGELS | PREDICTION | MATRICES | SOLUTE RELEASE
Journal Article
WORLD JOURNAL OF GASTROENTEROLOGY, ISSN 1007-9327, 09/2019, Volume 25, Issue 34, pp. 5097 - 5104
The survival and replication cycle of Helicobacter pylori (H. pylori) is strictly dependant on intragastric pH, since H. pylori enters replicative phase at an... 
ESOMEPRAZOLE | LANSOPRAZOLE | CURE RATES | Cytochrome P450 | COMPETITIVE ACID BLOCKER | Eradication | ERADICATION RATE | Optimization | INTRAGASTRIC PH | DUAL THERAPY | Helicobacter pylori | GASTRIC-ACID | Proton pump inhibitors | TRIPLE THERAPY | VONOPRAZAN | GASTROENTEROLOGY & HEPATOLOGY | Minireviews
Journal Article
Drug Development and Industrial Pharmacy, ISSN 0363-9045, 09/2019, Volume 45, Issue 9, pp. 1459 - 1467
Objectives: To develop novel dual release prototype capsule formulations of rabeprazole and evaluation of pharmacokinetic properties relative to the reference... 
relative bioavailability | assay | dissolution | Rabeprazole sulfide | pharmacokinetics | Dual release formulation | Rabeprazole | bioanalysis | proton pump inhibitor | CYTOCHROME-P450 | ESOMEPRAZOLE | CHEMISTRY, MEDICINAL | PROTON-PUMP INHIBITOR | OMEPRAZOLE | PLASMA | PHARMACOLOGY & PHARMACY
Journal Article
Journal of Electroanalytical Chemistry, ISSN 1572-6657, 09/2019, Volume 848, p. 113303
Esomeprazole is the most effective of the proton-pump inhibitors for the acid-related diseases and at first was examined for the electroanalytical purposes.... 
SWV determination at Au | LC-MS | Au surface analysis by AFM and OM | Degradation at IrOx | Esomeprazole | HPLC
Journal Article
Gastroenterology, ISSN 0016-5085, 08/2019, Volume 157, Issue 2, pp. 585 - 585
Journal Article
Equine Veterinary Education, ISSN 0957-7734, 08/2019, Volume 31, Issue 8, pp. 441 - 446
Oral omeprazole has been the cornerstone of equine gastric ulcer syndrome ( EGUS ) treatment for nearly 20 years. However, approximately 15–30% of equine... 
horse | treatment | omeprazole | esomeprazole | stomach | ulcer | Omeprazole | Stomach | Ulcer | Treatment | Esomeprazole | Horse | RISK-FACTORS | ACID-SECRETION | JUICE PH | ESOPHAGITIS | PHARMACOKINETICS | FORMULATIONS | SYNDROME EGUS | VETERINARY SCIENCES | ORAL OMEPRAZOLE | RANITIDINE | Stomach ulcer | Usage | Drug therapy
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 08/2019, Volume 34, Issue 8, pp. 1316 - 1328
Journal Article